

Apparatus and process for extracorporeal treatment of blood
5 with selective extraction of solutes.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims priority of French patent application No. 03 03257, filed on March 17, 2003 and the
10 benefit of U.S. Provisional Application No. 60/456,520, filed on March 24, 2003, the contents of which are incorporated herein by reference.

Background of the invention:

15 Filed of the invention:

The object of the present invention is a device and a method for the treatment of blood with selective extraction of solutes.

20 The object of this patent application is the filtration of blood to selectively separate and extract dissolved substances of chosen molecular size by means of extracorporeal systems designed for the separation of substances.

25

Description of related art:

Such systems are used for the treatment of blood containing solutes with different molecular weights. Such substances are, for example, urea, of molecular weight 60
30 daltons, phosphate (96-97 daltons), creatinine (113 daltons), vitamin B₁₂ (1 355 daltons), inulin (5 200 daltons), beta 2-microglobulin (12 000 daltons), and albumin (58 000 daltons).

Are hereafter termed 'small-sized molecules' molecules
35 of molecular weight less than about 2 000 daltons, 'medium-

sized 'molecules' molecules of molecular weight between 2 000 and 50 000 daltons, and 'large-sized molecules' molecules of molecular weight greater than 50 000 daltons (for example, proteins).

5

Such systems are often systems with extracorporeal membranes for the separation of solutes of molecular weight lower than that of albumin, applied to the treatment of renal insufficiency.

10

Improvements have always been sought in particular to ameliorate clearance, reduce treatment time and to make such systems simpler and less costly. The clearance of a solute is the amount of that solute in a given volume of treated blood.

15

In the field of dialysis, the first membranes used were highly permeable to small solutes of molecular weight up to 200 daltons. The clearance of small solutes depends on the permeability and diffusion capacity of the membrane used.

20

The lack of permeability of the first membranes for certain medium-sized solutes in the vitamin B₁₂ range (1 355 daltons) was blamed for the occurrence of multiple uraemic neuropathies.

25

To improve the clearance of medium-sized molecules, a first response was to add to the diffusion flow through the membrane a convection flow using high flow membranes with a molecular size cut-off value of 40 000 daltons. The cut-off value of a membrane is defined as the molecular size for which no more than 10 % of the solute travels through the membrane.

30

However, problems met in embodying this response include difficulty in controlling the ultrafiltration rate obtained by the convection flow, and the high loss of useful

35

plasma constituents such as hormones, vitamins and amino acids.

A second response for the improvement of the clearance of medium-sized molecules was haemo-filtration, a purely convective method for the elimination of solutes by the membrane. However, this method extracts a large amount of liquid, therefore requiring a compensatory pre- and (or) post-dilution with sterile liquid, and a membrane that is highly permeable to solutes of molecular weight up to 40 000 daltons. However, in a purely convective mode, the clearance depends on the mode of dilution (pre- or post-dilution), the blood flow rate and the infusate flow rate. With conventional haemo-filtration, the clearance of small-sized molecules is poorer than that obtained in haemodialysis mode. The clearance in haemo-filtration mode could reach that of haemodialysis if the infusate flow rate, the blood flow and the membrane area were increased. However, this is impractical, increases treatment cost and results in loss of amino acids and hormones. In addition, the blood flow rate is limited, in particular in patients with poor blood access.

Concerning the clearance of small-sized molecules, when it was discovered that this clearance was limited in haemo-filtration mode, the two processes of haemo-filtration and haemodialysis were combined. This simultaneous method was known as haemo-diafiltration. However, problems that arise include difficulty in precisely controlling the haemo-filtration flow, high loss of hormones and amino acids, the complexity of the system, the large quantities of sterile liquid and dialysate necessary, and consequently the high cost of the treatment.

Thus the use of a single filter working in different operating modes still failed to solve the particular problems of loss of molecules in a certain size range, and of high treatment cost.

5

A proposal was then made by Drs J.C. Kingswood and F.D.Thompson of a continuous haemo-filtration with no re-injection liquid: the treatment of the ultra-filtrate was performed by a second membrane also working in spontaneous
10 ultrafiltration. Figure 1 represents the dialysis set-up derived from this proposal.

The procedure is to treat a first ultra-filtrate, obtained from a first hollow fibre membrane, by sending it
15 through a second hollow fibre membrane in ultrafiltration mode. A first ultrafiltration is performed through a first high-flow membrane impermeable to molecules larger than 10 000 daltons. The apertures in the second membrane are smaller than those in the first.

20

As shown in Figure 1, at the outlet from the first membrane the unfiltered liquid, mainly containing large-sized molecules, is sent to the patient for re-injection. The first ultra-filtrate containing small- and medium-sized
25 molecules is filtered through the second membrane. The liquid not filtered by the second membrane, mainly containing medium-sized molecules, is collected in a waste bag. The second ultra-filtrate, mainly containing small-sized molecules, is re-injected in post-dilution via the
30 patient's venous line.

This saves consuming excessive amounts of sterile liquid in post-injection, and allows re-injection in the patient of a liquid containing few medium-sized molecules.

Even so, a high loss of nutrients, amino acids, glucose and vitamins occurs, and the clearance of small ions such as potassium is poor.

5

Accordingly, another dialysis device was designed. It was considered that the uraemic molecules that had to be removed were of molecular weight less than 200 daltons or between 10 000 and 40 000 daltons.

10 This consideration gave rise to a device composed of three filters, depicted in Figure 2.

A first filter has a cut-off value of about 40 000 daltons. The blood flows through this first filter to yield a first filtrate containing small-sized and medium-sized
15 molecules, i.e., molecules of molecular weight less than 40 000 daltons. The solutes of mass between 10 000 and 40 000 daltons are then eliminated by ultrafiltration through the second filter, which has a cut-off value below 10 000 daltons. The second filtrate is then treated by
20 haemo-filtration with a membrane with a cut-off value of about 200 daltons. Thus the purified filtrate, containing solutes between 200 and 10 000 daltons, is returned for post-infusion to the patient, who also receives the molecules of molecular weight greater than 40 000 daltons.,

25

However, the clearance of all the solutes depends on the ultrafiltration rate in filter 1, which cannot exceed 30 % of the blood flow, a value that is low compared with that attained in conventional haemodialysis. This raises
30 operating costs.

Lastly, Patent US 6,193,681 describes an apparatus to treat septicaemia in the blood, depicted here in Figure 3. The blood flows first through a UV irradiation device and
35 then through a blood concentrator before re-injection in the

patient. A secondary circuit is connected to a second outlet from the blood concentrator from which the fluid flows out through a filter followed by a membrane module and a dilution source, and is then injected upstream of the blood
5 concentrator.

There is in addition an analogous problem with plasmapheresis. Therapeutic exchange plasmapheresis is
10 carried out on patients whose plasma contains one or more harmful or toxic substances.

These solutes are eliminated from the plasma by the same principle as the elimination of solutes from blood, one difference being the greater molecular weight of the solutes
15 to be extracted from the plasma.

Thus recurrent problems have been encountered in the design of the devices in prior art, namely:

- High consumption of perfusion liquid,
- 20 - High losses of nutrients, amino acids, glucose and vitamins,
- Poor clearance of solutes,
- High cost of devices comprising several filters and pumps.

25

The problem addressed in this patent application is how to achieve selective elimination of molecules in one or more molecular weight ranges with good clearance, yet consume very small amounts of sterile liquid.

30 For example, for patients in a state of septicaemia, many medium-sized molecules have to be eliminated, while still maintaining satisfactory elimination of small-sized molecules. Septicaemia is characterised by abundant repeated release of specific pathogenic germs from an initial point
35 of infection.

Another potential problem is optimally adapting such a system for long-term therapy carried out in an intensive care environment without a risk of filter clogging. Such an adaptation can be achieved by judicious choice of mode of operation of the various filters, of use and appropriate positioning of means to regulate flow rate, of controlled flow rates and of hydraulic design of the lines.

Summary of the invention:

10

In order to solve the problem outlined above, the invention consists of an extracorporeal blood treatment device comprising at least one exchanger 1 equipped with at least one first inlet 2 for the blood to be treated, a first fluid outlet 4 and a second fluid outlet 5, an input line 10 for blood to be treated connected to the first inlet 2 of the exchanger 1, a blood output line (or venous line) 11 connected to the first outlet 4 of the exchanger 1, at least one treatment unit 21 comprising at least one first fluid inlet 22 and at least one first fluid outlet 24, the second outlet 5 of the exchanger 1 being in fluid communication with the first inlet 22 of the treatment unit 21, where the first outlet 24 from the treatment unit 21 is in fluid communication with the input line 10.

25

The invention also concerns an extracorporeal blood treatment method to be implemented by means of the extracorporeal blood treatment device comprising an exchanger 1 to which are connected a blood input line 10 and a blood output line 11 and a treatment unit 21, which method comprises the following steps: blood is sent through input line 10 connected to exchanger 1, filtered first in the exchanger 1 to produce a first filtrate, which is filtered at least a second time by the treatment unit 21 to produce a second filtrate, which is sent through the input line 10 for

35

pre-dilution of blood to be treated, and the blood is sent from the outlet from exchanger 1 to the output line 11.

Other advantages and characteristics of the invention will
5 be inferred from the following description.

Brief description of the drawings:

The description refers to the appended drawings, where:

Figure 1 shows the state of the art concerning the use of
10 two filters with different cut-off values and with post-dilution re-injection.

Figure 2 shows the state of the art concerning the use of three filters with different cut-off values and with post-dilution re-injection.

15 Figure 3 shows the state of the art of Patent US 6,193,681.

Figures 4 to 10 are schematic diagrams of the device for the treatment of physiological fluid according to the invention, together with various embodiments.

Figures 11 and 12 show the estimated results in terms of
20 clearance according to the molecular size of the solutes for two configurations of the device according to the invention.

Detailed description:

Figure 4 shows the principle of the invention in
25 diagrammatic form: blood inflow through an input line, its arrival in the exchanger and its outflow from the exchanger through an output line, together with the treatment of the first filtrate by a treatment unit and the injection of the liquid leaving the treatment unit in pre-dilution in the
30 arterial line. We can define this concept as a "cascade" of filtration steps with re-injection of the final filtrate in pre-dilution; in detail: a first filtrate is a second time filtrated, and the second filtrate is then injected at the inlet of the first filter, or in "pre-dilution".

Figure 5 shows the extracorporeal blood treatment device of the invention consisting of an exchanger 1 comprising a first inlet 2 for the blood to be treated, a first fluid outlet 4 and a second fluid outlet 5, an input line 10 for the blood to be treated, or arterial line, connected to the first inlet 2 of the exchanger 1, a blood output line, or venous line, 11 connected to the first outlet 4 of the exchanger 1. A treatment unit 21 comprises a first fluid inlet 22, and a first fluid outlet 24; the second fluid outlet 25 of the exchanger 1 is in fluid communication with the first inlet 22 of the treatment unit 21, and the first outlet 24 of the treatment unit 21 is in fluid communication with the input line 10.

The fluid communication between the first inlet 22 of the treatment unit 21 and the second outlet 5 of the exchanger 1 is made by a first duct 12.

The exchanger 1 can be equipped with a semi-permeable membrane 6 that divides it into a first chamber 7 and a second chamber 8. The first inlet 2 of the exchanger is in fluid communication with the first chamber 7 of the exchanger, the first outlet 4 of the exchanger is in fluid communication with the first chamber 7 of the exchanger, and the second outlet 5 of the exchanger is in fluid communication with the second chamber 8 of the exchanger.

The blood input line 10, termed the 'arterial line', connected to the first inlet 2 of the exchanger 1, the blood output line 11 termed the 'venous line', connected to the first outlet 4 of the exchanger and the first chamber 7 of the exchanger form part of an extracorporeal blood treatment circuit.

In one embodiment shown in Figure 6 the exchanger 1 can include a second inlet 3 in fluid communication with the

second chamber 8 and in fluid communication with a first source of dialysis liquid 9. In this mode of operation the blood and the dialysis liquid flow in opposite directions in each of the two chambers.

5

Figure 5 shows the treatment unit 21 equipped with a semi-permeable membrane 26 that divides it into a first chamber 27 and a second chamber 28.

10 The treatment unit 21 can advantageously have a second fluid outlet 25.

Thus the first outlet 24 of the treatment unit 21 is in fluid communication with the first chamber 27 of the
15 treatment unit 21 and the second outlet 25 of the treatment unit 21 is in fluid communication with the second chamber 28 of the treatment unit 21.

A first duct 12 is connected between the second outlet 5 of
20 the exchanger 1 and the first inlet 22 of the treatment unit 21, providing the fluid communication.

A second duct 40 is connected between the first outlet 24 of
25 the treatment unit 21 and the first inlet 2 of the exchanger 1, providing the fluid communication.

Alternatively, the first inlet 22 of the treatment unit 21
can be in fluid communication with either the second chamber
28 of the treatment unit 21, or with the first chamber 27 of
30 the treatment unit 21.

The second outlet 25 of the treatment unit 21 is in fluid communication with a first waste liquid discharge line 30, which discharge line 30 can connect the second outlet 25 of

the treatment unit 21 to a drain or to a first waste liquid container 31.

The treatment unit 21 can also have a second inlet 23, which
5 second inlet 23 is in fluid communication with the second chamber 28 and with a second source of dialysis liquid 29. In this operating mode of the treatment unit, shown in Figure 7, the dialysis liquid flows in the opposite direction to the physiological liquid arriving via the first
10 inlet 22.

The exchanger 1 and the treatment unit 21 have different characteristics. The membrane 6 of the exchanger 1 can be a high flow membrane, and the membrane 26 of the treatment
15 unit 21 can be a low flow membrane.

A low-flow membrane has a low water permeability. The ultrafiltration coefficient is between 2 and 10 ml/h,mmHg,m². A high-flow membrane has a much higher
20 hydraulic permeability. The ultrafiltration coefficient is 20 to 50mL/h,mmHg,m².

The exchanger or the treatment unit may comprise a hollow fiber dialyser (called also capillary filter) or a plate
25 dialyser , this means with membrane sheets.

Thus the permeability to molecules of the membrane 6 in the exchanger 1 is greater than the permeability to molecules of the membrane 26 in the treatment unit 21, at least above a
30 certain molecular weight.

More particularly, we can define a ratio or a difference between the two cut off values of the first membrane and the second membrane. Thus, we can define ratio of the cut-off value of the first membrane to the cut off value of the
35 second membrane less than or equal to three. In an other

way, we can define the difference in cut-off value between the first membrane and the second membrane is between 20 000 and 30 000 daltons. The cut-off value of the first membrane might be less than or equal to 40 000 daltons, and the cut-off value of the second membrane might be less than or equal to 10 000 daltons. In one embodiment the cut-off value of the first membrane is approximately 40 000 daltons and the cut-off value of the second membrane is approximately 10 000 daltons.

10

To re-infuse water to the patient being treated, it is possible to connect to the output line 11 a post-dilution line 50 connected to a first source of sterile liquid 51 and (or) to the input line 10 a pre-dilution line 60 connected to a second source of sterile liquid 61.

15

A second duct 40 makes a fluid connection between the first outlet 24 of the treatment unit 21 and the first inlet 2 of the exchanger 1.

20

The pre-dilution line 60 can be connected directly to said second duct 40 or directly to input line 10.

25

The different sources of sterile liquid 51, 61 can be bags of sterile liquid and (or) can be obtained by on-line preparation of sterile liquid from water drawn from a main supply system.

30

In the application of this invention to the special case of plasmapheresis, shown in Figures 9 and 10, the exchanger is a plasma filter. The plasma filter has a cut-off value between one million and five million daltons.

35

In this application, the exchanger or the treatment unit may comprise a hollow fiber dialyser (also called capillary

filter) or a plate dialyser, this means with membrane sheets.

Thus the treatment unit 21 includes a unit able to fixate at least one given substance. This unit can be an adsorption
5 cartridge, or a reactor, for example an electrophoresis cell.

The treatment unit can be equipped with a semi-permeable membrane 26 that divides it into a first chamber 27 with a
10 first outlet 24 and a second chamber 28 with a first inlet 22 and a second outlet 25. The second outlet is connected to a discharge line. The treatment unit can have a cut-off value less than or equal 250 000 daltons.

15 The cut off value can be less than or equal to 200000 dalton.

The treatment unit can have a cut-off value such that almost 100% of the albumin molecules (with 58000 daltons as
20 molecular weigh) can pass through the membrane.

Figure 10 shows a device comprising means to act on at least certain molecules 70. These means are connected to the first tube 12 between the second outlet 5 of the exchanger 1
25 and the first inlet 22 of the treatment unit 21. These means to act on at least certain molecules 70 can be a reactor, an adsorber or a radiation-based device, for example an electrophoresis, enzyme reaction, radiation, or ultraviolet irradiation device. The plasma filter can then have pores of
30 one micron. The treatment unit can have a cut-off value less than or equal to 90 000 daltons, letting proteins through to the patient's blood.

Another feature of the invention is that it adds a third
35 means of filtration to eliminate a further molecular weight

range, shown in Figure 8. The device can comprise at least one auxiliary exchanger 81 with a membrane 86 that separates it in a first chamber 87 that is in fluid communication with a first inlet 82 and a first outlet 84 and in a second
5 chamber 88 in fluid communication with at least one second outlet 85. The cut-off value of such an auxiliary exchanger will be less than the cut-off values of the other two membranes (6, 26).

The first inlet 82 of the auxiliary exchanger 81 is in fluid
10 communication with the second outlet 24 of the treatment unit 21, and one of the two outlets 84 or 85 of the auxiliary exchanger 81 is in fluid communication with the first inlet 2 of the exchanger 1.

15 A second waste liquid discharge line 90 connects the other outlet 84 or 85 of the auxiliary exchanger 81 to a drain, which drain can be a second waste liquid container 91.

Figure 8 shows the auxiliary exchanger operating in dialysis
20 mode: the auxiliary exchanger 81 has a second inlet 83 in fluid communication with the second chamber 88 of the auxiliary exchanger 81 and in fluid communication with a third source of dialysis liquid 89, the first outlet 84 of the auxiliary exchanger 81 being in fluid communication with
25 the first inlet 82 of the exchanger 1, the second outlet 85 of the auxiliary exchanger 81 being in fluid communication with a drain 91 via a second waste liquid discharge line 90.

The choice of the three membranes will be made very
30 precisely according to the patient and the treatment required according to the molecular weight ranges that are to be eliminated or retained. The first membrane 6 is appropriate for molecules of high molecular weight (preferentially in haemo-filtration mode), the second
35 membrane 26 is appropriate for molecules of mid-range

molecular weight (preferentially in haemo-filtration mode), and the third membrane 86 is appropriate for molecules of low molecular weight, i.e., preferentially in dialysis mode. The auxiliary exchanger 81 can still operate in
5 ultrafiltration mode if necessary. The choice of operating mode allows the treatment to be tailored to patient needs and to obtain optimal running with minimal clogging.

Concerning the regulation of the various fluid flow rates,
10 first means for regulating active liquid flow rate 101 is placed on the input line 10 connected to the first inlet 2 of the exchanger 1. Alternatively, the first means to regulate flow rate (101) can be placed exactly between the first inlet 2 of the exchanger 1 and the connection point
15 110 connecting the input line to the duct or upstream of the connecting point 110 connecting the input line 10 to the second duct 40.

In the first alternative, the pressure drop in the second duct 40 requires a lower positive pressure in the first duct
20 12 to reach the desired trans-membrane pressure (TMP) of the membrane 26.

Also, in the first alternative, it is not necessary to fit a pump on the second duct 40: a single pump 101 suffices for the second duct 40 and the arterial line 11.

25 In the second alternative, second means for regulating active liquid flow rate 102 is placed on the second duct 40 connecting the first outlet 24 of the treatment unit 21 to the first inlet 2 of the exchanger 1.

30 Third means for regulating active liquid flow rate 103 is placed on the first duct 12 connecting the second outlet 5 of the exchanger 1 to one of the inlets 22 or 23 of the treatment unit 21.

Also, fourth means for regulating active liquid flow rate
35 104 can be connected to the post-dilution line 50.

Fifth means for regulating active liquid flow rate 105 can be connected to the waste liquid discharge line 30 connecting the second outlet 25 of the treatment unit 21 to a drain 31.

5 In the configuration with at least three means of regulating flow rate 101 on the input line, 102 on the second duct 40 and 105 on the discharge line 30, special care must be taken to make sure the different flow rates set are compatible.

Sixth means for regulating active liquid flow rate 106 can
10 be connected to the pre-dilution line 60.

The means for regulating flow rate 101, 102, 103, 104 and 105 can be pumps and (or) valves. In particular, the means for regulating flow rate on the discharge line 30, or on the post-dilution line 50 or the pre-dilution line 60 will be
15 valves.

In a specific embodiment, the first post-dilution sterile liquid source 51 is a bag of sterile liquid and the first waste liquid container 31 connected to the discharge line
20 leaving the treatment unit is a bag of waste liquid. The device comprises a first balance 120 to weigh the bag of sterile liquid 51 and a second balance 121 to weigh the bag of waste liquid 31. Alternatively, a single balance 120-121 can weigh the bag of sterile liquid 51 together with the bag
25 of waste liquid 31.

In this case, a calculation and control unit 130 will receive the signals emitted by at least one balance 120-121 and will control the means for regulating liquid flow rate 101, 102, 103, 104 and 105.

30

In an embodiment, the device comprises a post-dilution line (50) connected, at one end, to the output line 11, and, at its other end, to a first source of sterile liquid (51); the device also includes fourth means for regulating liquid flow
35 rate (104) placed on the post-dilution line (50), a balance

(120, 121) to weigh the bag of sterile liquid (51) and the bag of waste liquid (31), fifth means for regulating liquid flow rate (105) placed on the waste liquid discharge line (30) connecting the second outlet (25) of the treatment unit (21) to a drain (31). The calculation and control unit (130) receives signals emitted by the balance (120, 121) and controls either the fourth means, or fifth means (105) or both the fourth and the fifth means to independently regulate the flow rate in each respective conduit.

10

According to an alternative solution, the device comprises a first independent balance (120) to weigh the bag of sterile liquid (51) and a second independent balance (121) to weigh the bag of waste liquid (31). The calculation and control unit (130) receives signals emitted by first and second balances (120, 121) and independently controls the fourth means to regulate liquid flow rate (104), and the fifth means to regulate liquid flow rate (105).

15

The calculation and control unit will periodically calculate the real flow rate or a parameter that is a function of the real flow rate, for example from the weight and the time interval between each two measurements. It will compare the real flow rate measured to the desired flow rate and will be able to control one or more means for regulating active liquid flow rate (101, 102, 103, 104, or 105).

20

Thus the quantities of sterile liquid and waste liquid, or their difference, can be monitored and controlled during the treatment. Knowing these weight quantities, the control unit can obtain a desired quantity of sterile liquid solution and waste liquid.

25

The hydric equilibrium can be well controlled in this way.

30

The device described above is applicable to plasmapheresis.

35

The invention also concerns a method for the extracorporeal treatment of blood to be implemented on a device for the extracorporeal treatment of blood comprising an exchanger 1 to which are connected a blood input line 10 and a blood output line 11, and a treatment unit 21, which method comprises the following steps:

- blood is sent through the input line 10 connected to the first inlet of the exchanger 1,
- 10 - The blood is first filtered in the exchanger 1, producing a first filtrate passing through the second outlet of the exchanger,
- the first filtrate is filtered at least a second time in the treatment unit 21, producing a second filtrate,
- 15 - the second filtrate is sent through the first outlet of the treatment unit to the input line 10 to effect a pre-dilution of the blood to be treated,
- the blood is sent out from the first outlet of the exchanger to the output line 11.

20

In particular, the method will include a second filtration carried out through a semi-permeable membrane 26 in a treatment unit 21 divided into a first chamber 27 and a second chamber 28, yielding the second filtrate and sending the non-filtered liquid to the drain line 30.

25

Another feature of the method is that the first filtration is carried out through a semi-permeable membrane 6 that divides the exchanger 1 into a first chamber 7 and a second chamber 8.

30

Another feature of the method is that the membrane 26 of the treatment unit filters molecules of molecular weight less

than the molecular weight of the molecules filtered from the membrane 16 of the exchanger.

Another feature of the invention is that the method includes
5 a step in which a sterile liquid is perfused in the blood output line 11 of the exchanger.

Another feature of the invention is that the method includes
10 a step in which a sterile liquid is perfused in the blood input line 10 of the exchanger.

Another feature of the invention is that the method uses an
exchanger membrane 16 with a cut-off value less than 40 000
dalton.

15 Another feature of the invention is that the method uses an
exchanger membrane 16 with a cut-off value less than 10 000
dalton.

20 Another feature of the invention is that the treatment
carried out is a plasmapheresis and the treatment unit
fixates at least one certain given substance.

Another feature of the invention is that the exchanger
25 membrane 16 has a cut-off value between one million and five
million dalton.

Another feature of the invention is that the treatment unit
membrane 16 has a cut-off value less than 250 000 dalton.

30

Simulations have been performed using filters with
different cut-off values. Figures 11 and 12 show the
estimated results in terms of clearance as a function of the
35 molecular weight of solutes for two configurations of the

device according to the invention. Figure 11 shows a first configuration using an exchanger with a cut-off value equal to 40 000 daltons, and a treatment unit using an exchanger with a cut-off value equal to 10 000 daltons. The clearance (curve 1) for molecules of molecular weight about 11 000 daltons is very good, while the clearance of small molecules is kept constant relative to an operating device equipped with a single filter (curve 2).

Figure 12 shows a second configuration for plasmapheresis using an exchanger with a cut-off value equal to 1 000 000 dalton, and a treatment unit using an exchanger with a cut-off value equal to 250 000 dalton. The clearance (curve 1') for molecules of molecular weight about 300 000 dalton is very good, while the clearance of medium-sized molecules is kept constant relative to an operating device equipped with a single filter (curve 2').

The invention offers numerous advantages. It allows:

- A three- to fourfold increase in the clearance of medium-sized molecules (or large-sized molecules in plasmapheresis) relative to a standard long-term treatment, with no increase in the quantity of exchange liquid and with no change in the standard clearance of small-sized molecules (small- and medium-sized in plasmapheresis),
- Large savings in sterile liquid, and therefore lower operating costs,
- Sufficient elimination of medium-sized molecules,
- Retention of trace elements and nutrients, which are returned to the patient,
- High volume filtration.

In particular, in the configuration illustrated in Figure 5, many other advantages are offered. Minimal means of

regulating flow rate are required: a peristaltic pump 101 on the arterial line and a pump 103 on the second duct 40 are sufficient to operate the device.

- 5 Also, the positioning of the means for regulating flow rate is well conceived: there is not necessarily any need for a pump on the second duct 40, although one can still be fitted, and the means of regulating flow rate 103 need not be very powerful. This permits long-term operation for
10 intensive care while avoiding heavy pore clogging of the various membranes.

Lastly, application of this operating scheme is envisaged for another mode of extracorporeal blood treatment, namely
15 plasmapheresis. Plasmapheresis operation is optimal when the membranes are carefully chosen and used.